Professor Lorraine O'Driscoll

Pharmacology

Prof. Lorraine O'Driscoll B.Sc(Hons), M.Sc(Res), Ph.D, F.T.C.D.
Email: lodrisc@tcd.ie
Phone: +353-1-896-2822
Location: Panoz Institute, Trinity College, Dublin 2, Ireland.

Module Coordinator and College Tutor.

RESEARCH INTERESTS

Lorraine holds a BSc (Hons) in Pharmacology, MSc (Res) in Clinical Pharmacology, and PhD in Biotechnology. Following her PhD, Lorraine worked on biotechnology/biomedical research studies for US and EU industry (includuing Berlex/Bayer HealthCare Pharmaceuticals; Archport Ltd-Axonobel; MediSyn Ltd; MedaNova Ltd.) before returning to academic research & teaching. At post-doctoral level, she gained experience at the Dana-Farber Harvard Cancer Institute and University of Miami. Prior to joining TCD in 2008, Lorraine most recently held the position of Senior Research Programme Leader, NICB and Lecturer in School of Biotechnology, DCU. Lorraine’s research group focuses on diagnostic, prognostic and predictive biomarkers; discovering new therapeutic targets; cancer cells communication via exosomes, microvesicles and CTCs; elucidating and circumventing resistance to targets agents and classical chemotherapy; associations between obesity, metabolic syndrome and cancer.

She has been a Principal Investigator and lead on cancer clinical trials for the All Ireland Cooperative Oncology Research Group since 2006. She is TCD’s Principal Investigator on SFI-supported Molecular Therapeutics for Cancer Ireland; Strand Leader of Irish Cancer Society-supported National Cancer Research Institute, Breast-PREDICT; and Lead Principal Investigator and Chair, EU FP7 EuropeanNetwork Cooperation in Science and Technology focussed on Exosomes & Microvesicles in health & Disease which brings together researchers from 27 European countries, 2 US universities, an Australian Institute and 7 industry partners. Lorraine’s background, drawing on expertise developed in industry and in academia, provides her with expertise in many areas of pharmaceutical sciences, pharmacology and biotechnology including extensive pre-clinical in vitro and in vivo studies and clinical trial development.

FINANCIAL SUPPORT

EU H2020 & FP7; Science Foundation Ireland (SFI); Health Research Board (HRB); Enterprise Ireland (E.I.); Danish Strategic Research Council/EU; Marie Keating Foundation; Irish Cancer Society (ICS); Higher Education Authority PRTLI; AdnaGen AG; Arla Health Foods; Pfizer; Bayer.